<code id='B75D64C34F'></code><style id='B75D64C34F'></style>
    • <acronym id='B75D64C34F'></acronym>
      <center id='B75D64C34F'><center id='B75D64C34F'><tfoot id='B75D64C34F'></tfoot></center><abbr id='B75D64C34F'><dir id='B75D64C34F'><tfoot id='B75D64C34F'></tfoot><noframes id='B75D64C34F'>

    • <optgroup id='B75D64C34F'><strike id='B75D64C34F'><sup id='B75D64C34F'></sup></strike><code id='B75D64C34F'></code></optgroup>
        1. <b id='B75D64C34F'><label id='B75D64C34F'><select id='B75D64C34F'><dt id='B75D64C34F'><span id='B75D64C34F'></span></dt></select></label></b><u id='B75D64C34F'></u>
          <i id='B75D64C34F'><strike id='B75D64C34F'><tt id='B75D64C34F'><pre id='B75D64C34F'></pre></tt></strike></i>

          leisure time

          leisure time

          author:entertainment    Page View:18839
          President Biden speaks on the Cancer Moonshot initiative at the John F. Kennedy Library in 2022. Evan Vucci/AP

          WASHINGTON — The next chapter of President Biden’s moonshot to end cancer has landed. While the new goals are inspiring hope among cancer researchers, not everyone is impressed.

          The president early Wednesday morning unveiled a slew of federal plans and private-sector agreements to fuel the relaunched Cancer Moonshot, a project to improve treatments and halve cancer deaths in the next 25 years. Among roughly 50 new programs and partnerships are multimillion-dollar pledges to advance testing, data pools, clinical trials and outreach efforts.

          advertisement

          It is the latest phase of a project Biden first launched as vice president in the wake of his son Beau’s death from brain cancer in 2015. But while the first moonshot funneled money almost entirely to early-stage cancer research, its sequel is broadening efforts to prevent cancer deaths — particularly through anti-smoking efforts — and introduces a new focus on research infrastructure and patient engagement that some cancer researchers have applauded.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Amylyx's ALS drug launch starts strong. It could be trouble for FDA
          Amylyx's ALS drug launch starts strong. It could be trouble for FDA

          MollyFerguson/STATBehindthestellarcommerciallaunchofAmylyxPharmaceuticals’treatmentforALSliesanuncom

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Anavex keeps shifting the goalposts in its clinical trials

          MollyFerguson/STATAnavexLifeSciencesisinatoughspot.Theserialdissemblerofclinicaltrialresultsmightbef